Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Other Routine +

MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

MediciNova Clears Trial Hurdle for MN-001; Q3 Data Release Looms Amidst ALS Pipeline Progress

By The Northwire Desk — AI Analysis May 26, 2026 · 19:00 4875 NaN
Executive Summary
  • The most recent release (May 26, 2026) confirms completion of Last Patient Last Visit (LPLV) for the Phase 2 trial MN-001-NATG-202 evaluating tipelukast (MN-001).
  • Top-line data for this trial is expected in Q3 2026.
  • Historical progression shows consistent execution: Enrollment completed Nov 2025, mechanistic validation published Oct/Dec 2025, and LPLV achieved May 2026.
  • Parallel pipeline updates include MN-166 (ibudilast) trials for ALS (COMBAT-ALS), Chemotherapy-induced Peripheral Neuropathy (OXTOX), and Brain Metastasis research published April 2026.
  • The company maintains regulatory designations including Orphan Drug and Fast Track status for ALS indications.
Material Impact
  • Execution Milestone: Completion of LPLV is a procedural milestone that confirms the study has finished data collection as planned, reducing execution risk regarding trial delays.
  • Timeline Confirmation: The Q3 2026 data release date aligns with previous guidance (Summer 2026) provided in November and December 2025 releases; no significant deviation or acceleration is noted.
  • Pipeline Diversification: While MN-001 progresses, the April 2026 publication regarding MN-166 for brain metastasis adds a new potential indication but remains preclinical/early translational compared to the late-stage ALS program.
  • Market Expectation: As this trial completion was anticipated following the November 2025 enrollment announcement, the news is priced in and lacks immediate surprise factor required for "Material" classification.
  • Risk Profile: The company remains dependent on binary clinical outcomes; no data has been released yet to validate efficacy or safety.
4875 · Price
Company Overview
  • Company: MediciNova is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for inflammatory, fibrotic, and metabolic diseases.
  • Flagship Project 1 (MN-166/Ibudilast): A PDE inhibitor with anti-inflammatory properties currently in Phase 2b/3 trials for ALS (COMBAT-ALS) and Phase 2 for CIPN. Holds Orphan Drug and Fast Track designations from the FDA.
  • Flagship Project 2 (MN-001/Tipelukast): An orally bioavailable small-molecule targeting leukotriene receptors, PDE3/4 inhibition, and 5-LO inhibition. Currently in Phase 2 for hypertriglyceridemia and NAFLD associated with Type 2 diabetes.
  • Mechanism: Multi-modal activity including anti-inflammatory, antifibrotic, and lipid-modulating effects.
Read the original news release →

More from NaN

Jun 30, 2026 · 08:00

Clinical-stage biotech advances late-stage neurology and metabolic assets with H2 2026 data catalysts on track.

Other Jun 08, 2026 · 08:00

Late-stage biotech advancing MN-166 across neurology and oncology, with patent wins reinforcing IP moats while pivotal clinical data remains pending.

M&A / Property Apr 27, 2026 · 19:00

MediciNova’s Ibudilast Gains Brain Metastasis Validation Ahead of ALS Readout

Other Jan 29, 2026 · 18:00

MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN-166 (ibudilast) in ALS patients

Other Jan 06, 2026 · 09:00

2026 New Year's Greetings from the CEO

Other Dec 18, 2025 · 06:00

MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy

Other